Results 151 to 160 of about 189,217 (189)
Aims At Koç University School of Medicine, a one‐week rational pharmacotherapy (RPHM) programme, modelled after WHO 6‐step, has been introduced in the fourth‐year curriculum to improve prescription skills. For efficient problem‐based learning (PBL) sessions on a prespecified topic, students need to brush up on basic pharmacology knowledge, so we ...
Sinem Ezgi Gülmez +2 more
wiley +1 more source
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley +1 more source
Compensation preferences of home-based disabled beneficiaries in the long-term care insurance system in Guangzhou, China. [PDF]
Qian Y +10 more
europepmc +1 more source
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló +5 more
wiley +1 more source
Evaluation of long-term care insurance pilot city policies in China: a cross-sectional study. [PDF]
Du K, Liu Y, Hu Y.
europepmc +1 more source
Aims Hypertension is a leading modifiable risk factor for cardiovascular mortality worldwide. This study aimed to evaluate 25‐year trends in antihypertensive agent (AHA) utilization in Croatia between 2000 and 2024. Methods We conducted a national, population‐based analysis using IMS and IQVIA pharmaceutical databases.
Andrej Belančić +4 more
wiley +1 more source
Assessing the role of long-term care insurance in shaping living arrangements of older adults: evidence from China. [PDF]
Zhu Z, Bai C.
europepmc +1 more source
Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria
Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova +5 more
wiley +1 more source
Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang +6 more
wiley +1 more source
Disease trajectories and medical expenditures of older adults with disabilities: insights from China's long-term care insurance program. [PDF]
Zeng L +7 more
europepmc +1 more source

